Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter

Some five months after announcing the planned retirement of its longtime CEO Doug Ingram over what the helmsman dubbed an “ironic twist of fate” involving the health of his family members, Sarepta | Some five months after announcing the planned retirement of its longtime CEO Doug Ingram over what the helmsman dubbed an “ironic twist of fate” involving the health of his family members, Sarepta Therapeutics has found a permanent replacement.

Raccontata dabiopharmadive.comendpoints.newsstatnews.comfiercepharma.com